Our Commitment
We want to create value in areas of unmet medical need and engage with communities and society to improve lives – for humans and animals.
Search
Boehringer Ingelheim - Value Through Innovation
Boehringer Ingelheim is one of the world's leading research-driven pharmaceutical companies with 130 years of experience.
Immunology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in immunology.
About Boehringer Ingelheim Partnering Days
Find out more about our partnering days and how we can work together to accelerate your science
Effective vaccine against most virulent strains of Marek's disease affecting poultry
Effective vaccine against most virulent strains of Marek's disease affecting poultry launched in Egypt
Boosting performance with an inclusive performance culture
Boosting performance of organizations with an inclusive performance culture
Research Beyond Borders Partnering
Our Research Beyond Borders team is looking for emerging science and technology opportunities. Learn more about partnering with us.
Mutual benefit: Patient-centricity in clinical trials
Uli Broedl and Bronwyn Lewis share what they learnt from a successful patient organization collaboration on clinical trial design.
Research Beyond Borders overview
Learn more about how our Research Beyond Borders team is uncovering new ideas and new science.
Boehringer Ingelheim Opens New Scientific Office in Kenya as Part of its Commitment to Improve Human and Animal Health in Africa
Boehringer Ingelheim has officially opened its new scientific office in Nairobi, Kenya.
More Health Overview
Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.
Boehringer Ingelheim Awarded Top Employer In 29 Countries Including The Kingdom of Saudi Arabia
Boehringer Ingelheim Awarded Top Employer In 29 Countries Including The Kingdom of Saudi Arabia And The United Arab Emirates
Oncology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic
2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic
Technologies
We are expanding our global network of technology partners Learn more about partnering with us.
Interview: Excellence in stem cell treatments
Acquisition of GST reflects the potential of biotechnology research. Goal is to provide breakthrough therapies for diseases in companion animals.
Green Chemistry
Green Chemistry is critical for us as it balance the long-term sustainability of business, society, and the environment.
Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19
Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19
COVID-19 Global Access Commitment with Gates Foundation
Boehringer Ingelheim commits to provide global access to COVID-19 therapeutics by signing a communiqué with the Bill & Melinda Gates Foundation.
Human Health Partnering
Human Health Partnering
Boehringer Ingelheim collaborates with local universities in Nairobi, Kenya to introduce
Boehringer Ingelheim collaborates with local universities in Nairobi, Kenya to introduce development program for young professionals
Parasiticides
Parasiticides
Animal Health Partnering
Animal Health Partnering
BI Access to Healthcare Strategy_Availability
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering More Health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.
Boehringer Ingelheim Teams Up with the Lebanese Pulmonary Society (LPS) in its Fight against COVID-19
Boehringer Ingelheim Teams Up with the Lebanese Pulmonary Society (LPS) in its Fight against COVID-19